GBS INC (GBS)

Company Profile

GBS, Inc. operates as a biosensor diagnostic technology company. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2020-12-23. The Company’s products include Biosensor Platform Technology, Saliva Glucose Test (SGT) and Saliva Glucose Biosensor (SGB). The Biosensor Platform is a SGB-based modified Organic Thin Film Transistor (OTFT). The OTFT structure consists of a source and drain electrode, a semiconducting layer, a gate electrode, an optional separation (or dielectric) layer, all printed on a substrate material and superimposed by a polyelectrolyte membrane/enzyme layer onto which the analyte is placed. The SGT consists of SGB, which is a single use disposable saliva biosensor, and Software app, which is a smart device or a dedicated reader that interfaces the SGB with its digital information system. The SGB interacts with the glucose in the saliva and initiates an electrochemical reaction, producing an electrical signal directly correlated to the amount of glucose present in the saliva.

Company Info

GBS INC

142 West 57th Street, 11th Floor

New York City NEW YORK

P: 16462336971.0

Employees: 12

Website: https://gbs.inc/